Abstract
Objective.Despite correlation between the completeness of surgical cytoreduction and survival for patients with advanced ovarian cancer, relatively few undergo complete cytoreduction. This study was initiated to prospectively determine the ability to surgically eliminate all visible disease in patients with stage IIIC and IV epithelial ovarian cancer and the associated impact on survival.Methods.Between 1990 and 1996, 163 consecutive patients underwent primary cytoreduction. The goal was the excision or ablation of all visible disease prior to initiation of systemic platinum-based combination chemotherapy. A multivariate analysis determined which clinical and pathologic variables influenced the probability of achieving complete cytoreduction (logistic regression) and survival (Cox proportional hazards model).Results.One hundred thirty-nine patients (85.3%) underwent removal of all visible tumor, 22 (13.5%) had cytoreduction to ≤1 cm residual disease, and 2 (1.2%) had unresected bulky disease. The median and estimated 5-year survival for the entire cohort was 54 months and 48%, respectively. The probability of achieving complete cytoreduction was influenced independently by the preoperative Gynecologic Oncology Group performance status (0–1 vs 2–3,P= 0.04), the number of mesenteric and intestinal serosal implants (≤75 vs >75 implants,P= 0.005), and stage (IIIC vs IV,P= 0.006). The probability of survival was independently influenced by age (≤61 vs >61 years,P= 0.003), volume of ascites (≤1 vs >1 liter,P= 0.01), stage (IIIC vs IV,P= 0.04), histology (clear cell and mucinous vs all other,P= 0.03), and the completeness of cytoreductive operation (complete vs incomplete cytoreduction,P= 0.02).Conclusions.Complete cytoreduction is possible for the majority of patients and improves survival, even compared to operations with minimal (≤1 cm) residual disease. Unless their medical condition prohibits anesthesia and surgery, patients with advanced epithelial ovarian cancer should undergo primary cytoreductive surgery with the intention of complete tumor removal.
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
